Celltrion said it surpassed 4 trillion won in annual revenue and 1 trillion won in operating profit for the first time.
In a regulatory filing on Wednesday, the company said 2025 revenue rose 17% from a year earlier to 4.1625 trillion won, while operating profit surged 137.5% to 1.1685 trillion won on a consolidated basis. Operating margin climbed 14.3 percentage points to 28.1%.
Celltrion attributed the results to steady growth in established products and rapid expansion of higher-margin newer drugs. Global biopharmaceutical sales rose 24% to 3.8638 trillion won as products including Remsima SC, Yuflyma, Vegzelma, Zymfentra, Stekima, Omliclo and Stoboclo-Osenvelt gained traction alongside Remsima, Truxima and Herzuma. New products accounted for 54% of sales.
Remsima held a 59% market share in Europe and 30% in the United States, the company said. Truxima posted market shares in the 30% range in the U.S. and Europe. Herzuma ranked No. 1 in Europe and had a 75% share in Japan. Yuflyma and Vegzelma also ranked No. 1 in Europe.
Five products — Stekima, Stoboclo-Osenvelt, Omliclo, Aptozma and Idencelt — were launched in the second half of last year but still generated more than 300 billion won in annual sales, Celltrion said.
For 2026, Celltrion set a revenue target of 5.3 trillion won. It said it will pursue a “selection and concentration” strategy by reducing the share of high-cost products and focusing bids on newer, higher-net-profit products, aiming to lift the new-product sales share to about 70%.
The company also said its Branchburg, New Jersey, manufacturing facility, whose acquisition was completed at the end of last year, will begin generating contract manufacturing (CMO) revenue this year. Celltrion said it signed a deal with Eli Lilly to supply biopharmaceutical products worth 678.7 billion won over three years through 2029.
A Celltrion official said the company expects strong growth to continue this year as structural cost improvements take hold and the impact of new product launches becomes more pronounced. The official said Celltrion will work to expand its biosimilar pipeline and secure new growth engines, including new drugs and CMO, to become a global big pharma company.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.